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AC1
OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL
CONDITIONS (2015-2018)
Lidonnici D1, Lanati EP1, Niedecker S2, Isernia M1, Ronco V1
1MA Provider Srl, Milano, Italy, 2MA Provider Sagl, Lugano, Switzerland
OBJECTIVES: To track and analyse the economic negotiated conditions (Managed
Entry Agreements [MEAs], monitoring registries, discounts) of novel drugs reim-
bursed in Italy through Official Journal publications.METHODS: Eighty-eight drugs
which were granted EU approval between May 2015 and May 2018 and completed
the P&R process in Italy were tracked and categorized by type and therapeutic area
in a monthly updated database. Negotiated MEAs, applied confidential discounts
and monitoring registries were evaluated through Official Journal publications.
RESULTS: Categorization by type yielded 26.1% (23) orphan drugs (EU), 19.3% (17)
innovative (AIFA), 5.7% (5) classified as orphan and innovative drugs and 48.9% (43)
others; 14.8% (13) oncological drugs, 11.3% (10) oncohaematological and 73.9% (65)
others by therapeutic area. Data analysis showed that 33% (29/88) of drugs hadMEAs
as approval condition; 26 (29.5%) drugs had one single MEA, 3 drugs (3.5%) had two
MEAs (payment-by-results + budget cap or price-volume + capping) and the
remaining 59 had none. Further analysis of the total 32 (31 and 1 undisclosed) MEAs
showed that 31.3% (10) had price-volume agreements, 25% (8) budget cap, 15.6% (5)
cost-sharing agreements, 12.5% (4) payment-by-results, 9.3% (3) had capping.
Furthermore, AIFA set a market access agreement, a flat fee per patient, for Zalmoxis
(3.1%). Twenty-two (75.9%) of the screened drugswithMEAshadmonitoring registries
and 16 (55.2%) had confidential discounts. CONCLUSIONS: Data evaluation showed
an unbalance between outcome based and non-outcome based (financial) MEAs
suggesting that regulatory attention is predominantly on the economic impact of new
drugs; althoughAIFA recognised the added value of a newpatient specific cell therapy
by applying flat fee per patient. The low number of outcome basedMEAs, though, are
counterbalanced by the large number of monitoring registries requested. Budget cap
and price-volume agreements are the most commonly negotiated MEAs.
AC2
USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR
UNIVERSAL HEALTH COVERAGE IN INDONESIA
Wasir R1, Irawati S2, Makady A3, Postma MJ2, Goettsch W4, Feenstra T1,
Buskens E1
1University Medical Center Groningen, Groningen, The Netherlands, 2University of
Groningen, Groningen, The Netherlands, 3The National Healthcare Institute (ZIN),
Diemen, The Netherlands, 4The National Healthcare Institute (ZIN), Utrecht University,
Diemen, The Netherlands
OBJECTIVES: This study aimed to define the problems of the current use of the
e-Catalogue and the National Formulary (NF) - two elements of medicine pricing
and reimbursement policies in Indonesia for achieving universal health coverage
(UHC) - by examining the knowledge and attitudes of stakeholders. Specifically, to
investigate (1) the perceived challenges involved in the further implementation of
the e-Catalogue and the NF, (2) the reasons of prescribing medicines not listed
in the NF, and (3) possible improvements in the acceptance and use of the
e-Catalogue and the NF. METHODS: Semi-structured interviews were conducted
with stakeholders (policymakers, healthcare providers, pharmaceutical industry
representative and experienced patients) to collect the qualitative data. The data
were analysed using directed content analysis, following the guidelines of the
COnsolidated criteria for REporting Qualitative studies (COREQ) in reporting the
findings. RESULTS: Interestingly, 20 of 45 participants decided to withdraw
from the interview due to their lack of knowledge of the e-Catalogue and the NF. All
25 stakeholders who fully participated in this research were in favor of the
e-Catalogue and the NF. However, interviewees identified a range of challenges. A
major issue was the lack of harmonization between the lists of medicines in the
e-Catalogue and the NF. Several system and personal reasons for prescribing
medicines not listed in the NF were identified. Important reasons were a lack of
incentives for physicians as well as a lack of transparent and evidence-based
methods of selection for the medicines to be listed in the NF. CONCLUSIONS: The
e-Catalogue and the NF have not been fully utilized for achieving UHC in Indonesia.
Some possible improvements suggestedwere harmonization ofmedicines listed in
the e-Catalogue and the NF, restructuring incentive programs for prescribing NF
medicines, and increasing the transparency and evidence-based approach for
selection of medicines listed in the e-Catalogue and the NF.AC3
DISCORDANT DESIGNATIONS OF BREAKTHROUGH DRUG INNOVATION:
FRANCE VERSUS THE UNITED STATES
Sam E1, Adamson BJ2, Garrison LP3
1French Healthcare products Pricing Committee (CEPS), French Ministry of Health, Paris,
France, 2The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute,
University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA,
USA
OBJECTIVES: Approaches to identify and encourage new innovative, breakthrough
drugs vary greatly among countries. The United States (US) Food and Drug
Administration (FDA) “breakthrough-therapy” designation created in 2012
expedites testing and approval. In France, Improvement of the Medical Benefit
(ASMR) valued from I-III by the FrenchNational Authority for Health (HAS) qualify a
drug as innovative and influence pricing. We aimed to evaluate the consistency of
FDA and HAS designations and frequency of discordant decisions.METHODS: We
conducted a retrospective analysis of approved drug innovation classifications.We
developed a dataset of 2013-2018 approvals designated as “breakthrough-therapy”
by the FDA and/or innovative by HAS. New indications were excluded. All data
sources are publically available from government agencies. Variables included
approval year, indication, market authorization type, FDA breakthrough
designation, ASMR value obtained, and other FDA programs (orphan drug, fast
track, and accelerated). RESULTS: We identified 57 drug approvals meeting study
inclusion/exclusion criteria. More than half (n¼30) were indicated for cancer. In
the subset of drugs (n¼37) classified by FDA and assigned an ASMR value by HAS
(n ¼ 37), an innovative designation was more common in the US (78% vs 49% in
France). Yet, there was substantial discordance regarding which drugs were
defined as innovative. Two of every three breakthrough-therapies approved
in the US were not considered as innovative in France. In French review,
44% considered innovative were not classified as breakthrough-therapy in the US.
In the sample, 73% had discordant designations in FDA versus HAS.
CONCLUSIONS: Classification of the innovativeness of new drugs led to
substantially different conclusions in France compared to the US. As
pharmaceutical companies are incentivized to seek breakthrough and innovative
designations during market access, these mixed signals may affect their
investments and thus, ultimately, both innovation and access to medicines.
AC4
RETROSPECTIVE ANALYSIS OF INAPPROPRIATE MEDICATION
PRESCRIPTION INDICATORS IN ELDERLY POPULATION IN ITALY
Galimberti F1, Casula M1, Olmastroni E1, Russo V2, Piscitelli A2, Orlando V2,
Menditto E2, Tragni E1
1Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of
Milan, Milan, Italy, 2University of Naples Federico II, Naples, Italy
OBJECTIVES: To retrospectively evaluate indicators of appropriate prescribing in
an elderly population using Regional administrative prescription databases.
METHODS: This study funded by the Italian Medicines Agency. We evaluated a set
of explicit criteria, including a list of inappropriate drugs (ERD) in elderly (based on
validated Beers, STOPP and EU-(7)-PIM criteria), a list of drugs with high
anticholinergic burden (ACB) and with elevated sedative load (SL), has been
selected, updated, and adapted to Italian context. The study population was
composed by all patients over 65 years followed by a general practitioner (GP) of
four local health units (LHUs) in Lombardy and Campania. These criteria were
applied to the administrative databases of the outpatient drug prescriptions
(reimbursable by the NHS) in 2016. RESULTS: The number of GPs for the four LHUs
involved (Lecco, Bergamo, Napoli1 Centro and Napoli2 Nord) were 205, 661, 744 and
794, with a mean of 369, 324, 225, 170 patients over 65 for each GP, respectively. For
LHUs in Lombardy, the percentages of elderly who received at least an ERD drug
were 37.6% for Lecco (median 37.2; IQR 33.9-40.6) and 43.0% for Bergamo (median
42.7; IQR 38.6-47.5). For LHUs in Campania, more than 60% of patients were
involved in the ERD list. In all LHUs, the most inappropriate drug prescribed was
diclofenac. A high anticholinergic burden (ACB score3) was found for 6.0%, 8.0%,
6.7% and 7.0% of patients belonging to the four LHUs, while an elevated sedative
load (SL score3) was observed in less than 1% of patients. CONCLUSIONS: These
results show that the prescription of potentially inappropriate drugs in elderly
patients is widespread, with some remarkable geographical differences. Therefore,
it is necessary to implement local strategies to improve the rational use of drugs.
This will enhance safe prescribing practices, reducing costs associated with
inappropriate/unnecessary prescribing.
